cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Horizon Therapeutics Public Ltd Co
16 own
25 watching
Current Price
$115.66
$0.05
(0.04%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
22,725.06M
52-Week High
52-Week High
115.80000
52-Week Low
52-Week Low
60.03000
Average Volume
Average Volume
0.8M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
47.3668
iconMarket Capitalization22,725.06M
icon52-Week High115.80000
icon52-Week Low60.03000
iconAverage Volume0.8M
iconDividend Yield--
iconP/E Ratio47.3668
What does the Horizon Therapeutics Public Ltd Co do?
Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company's marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. Its products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The company has collaboration agreements with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer; and Alliance for Lupus Research (ALR) to study the effect of RAYOS on the fatigue experienced by systemic lupus erythematosus (SLE) patients. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Read More
How much money does Horizon Therapeutics Public Ltd Co make?
News & Events about Horizon Therapeutics Public Ltd Co.
InvestorPlace
2 months ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025 The post 3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025 appeared first on ...
Business Wire
2 months ago
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA showing a reduction in the formation of subclinical...
Business Wire
3 months ago
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA for the treatment of active TED. TEPEZZA is the first and only medicine approved for active TED in Brazil, filling a significant unmet need for those who are living with this...
Business Wire
3 months ago
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a series of analyses demonstrating the risk of hearing-related events among people with Graves disease and TED, including among those treated with TEPEZZA. TEPEZZA is the first and only medicine approved by the U.S. Food...
Business Wire
3 months ago
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a new analysis from the N-MOmentum clinical trial of UPLIZNA demonstrating the utility of a robust adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD...
Frequently Asked Questions
Frequently Asked Questions
What is Horizon Therapeutics Public Ltd Co share price today?
plus_minus_icon
Can Indians buy Horizon Therapeutics Public Ltd Co shares?
plus_minus_icon
How can I buy Horizon Therapeutics Public Ltd Co shares from India?
plus_minus_icon
Can Fractional shares of Horizon Therapeutics Public Ltd Co be purchased?
plus_minus_icon
What are the documents required to start investing in Horizon Therapeutics Public Ltd Co stocks?
plus_minus_icon
What is today’s traded volume of Horizon Therapeutics Public Ltd Co?
plus_minus_icon
What is today’s market capitalisation of Horizon Therapeutics Public Ltd Co?
plus_minus_icon
What is the 52-Week High and Low Range of Horizon Therapeutics Public Ltd Co?
plus_minus_icon
What percentage is Horizon Therapeutics Public Ltd Co down from its 52-Week High?
plus_minus_icon
What percentage is Horizon Therapeutics Public Ltd Co up from its 52-Week Low?
plus_minus_icon
Current Price
$115.66
$0.05
(0.04%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00